Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Green(Hospital South West Jutland), Michael Møller(Hospital South West Jutland), Ken H. Young(Duke Medical Center), Ronald S. Go(Mayo Clinic), Zijun Y. Xu‐Monette(Duke University), Torben Mourits‐Andersen(Hospital South West Jutland), Attilio Orazi(Texas Tech University), Carlo Visco(University of Verona), Ole Gadeberg(Hospital South West Jutland), Ole Nielsen(Hospital South West Jutland), Mikael Frederiksen(Hospital South West Jutland), Lars Møller Pedersen(Hospital South West Jutland)
Cited by 682
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin
|Journal of Clinical Oncology|1999|697
Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years
|Journal of Oncology Practice|2017|447